Literature DB >> 12691794

Relapse of ocular symptoms after remission of myasthenia gravis--a comparison of relapsed and complete remission cases.

Nobuo Wakata1, Hiroaki Iguchi, Hideki Sugimoto, Nobuatu Nomoto, Teruyuki Kurihara.   

Abstract

Extended thymectomy and high-dose alternate-day prednisolone administration may increase the chance of remission in myasthenia gravis (MG) patients. In cases of remission, ocular symptoms sometimes reappear after a gradual decrease or discontinuation of prednisolone administration. We compared relapsed patients with those who experienced complete remission. We found that the period from onset of MG to thymectomy and initiation of prednisolone administration was longer in the relapsed cases, which suggests that early thymectomy and administration of prednisolone can lead to a superior outcome in MG patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12691794     DOI: 10.1016/s0303-8467(02)00104-x

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  4 in total

1.  Clinical predictors for the prognosis of myasthenia gravis.

Authors:  Lili Wang; Yun Zhang; Maolin He
Journal:  BMC Neurol       Date:  2017-04-19       Impact factor: 2.474

2.  Clinical Features and Prognosis of Ocular Myasthenia Gravis Patients with Different Phenotypes.

Authors:  Li-Li Wang; Yun Zhang; Mao-Lin He
Journal:  Chin Med J (Engl)       Date:  2015-10-05       Impact factor: 2.628

3.  Lower number of plasma exchange sessions and glomerular filtration rate decline are associated with second relapses in patients with myasthenia gravis.

Authors:  Vedran Premuzic; Ervina Bilic; Branimir Ivan Sepec; Mirea Hancevic; Hrvoje Bilic; Barbara Sitas; Rujana Sprljan Alfirev; Bojan Jelakovic
Journal:  Medicine (Baltimore)       Date:  2020-02       Impact factor: 1.817

4.  Utilization of Decision Tree Algorithms for Supporting the Prediction of Intensive Care Unit Admission of Myasthenia Gravis: A Machine Learning-Based Approach.

Authors:  Che-Cheng Chang; Jiann-Horng Yeh; Hou-Chang Chiu; Yen-Ming Chen; Mao-Jhen Jhou; Tzu-Chi Liu; Chi-Jie Lu
Journal:  J Pers Med       Date:  2022-01-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.